Known targets — ChEMBL curated mechanism
CHRM1CHRM2CHRM3CHRM4CHRM5SLC6A2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10598262 | 0.98 | KCNH2 (0.45) | LMNACYP2D6CYP2C9CYP2C19KCNH2 | |
| SCHEMBL10598903 | 0.98 | KCNH2 (0.45) | LMNACYP2D6CYP2C9CYP2C19KCNH2 | |
| SCHEMBL10599444 | 0.95 | CYP3A4 (0.43) | LMNACYP2D6CYP2C9CYP2C19KCNH2 | |
| SCHEMBL11725693 | 0.90 | LMNA (0.50) | LMNACYP2D6CYP2C9CYP2C19KCNH2 | |
| Choline SCHEMBL506429 | 0.88 | CYP3A4 (0.46) | LMNACYP2D6CYP2C9CYP2C19KCNH2 | |
| SCHEMBL10756870 | 0.87 | ALDH1A1 (0.42) | LMNACYP2D6CYP2C9CYP2C19TSHR | |
| Choline SCHEMBL28623707 | 0.86 | CYP3A4 (0.46) | LMNACYP2D6CYP2C9CYP2C19KCNH2 | |
| SCHEMBL10598909 | 0.85 | ALDH1A1 (0.41) | LMNACYP2D6CYP2C9CYP2C19HTT | |
| SCHEMBL10598268 | 0.85 | ALDH1A1 (0.41) | LMNACYP2D6CYP2C9CYP2C19HTT | |
| Choline SCHEMBL28992902 | 0.85 | CYP3A4 (0.45) | LMNACYP2D6CYP2C9CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220265857-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2022-08-25 | — | — | US | disclosed |
| EP-3386484-B1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11285222-B2 | Compositions and methods for delivery of agents | MODERNATX, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20200206362-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | Moderna TX, Inc. (US) | 2020-07-02 | — | — | US | disclosed |
| US-10556018-B2 | Compositions and methods for delivery of agents | ARES CAPITAL CORPORATION, AS AGENT | 2020-02-11 | — | — | US | disclosed |
| US-20190117798-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-10207010-B2 | Compositions and methods for delivery of agents | MODERNATX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| EP-0154977-B1 | GLYCERIN-ETHER PHOSPHATIDES, THEIR PREPARATION AND USE | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1989-05-17 | — | — | EP | disclosed |
| US-4694084-A | Glycerol ether phosphatides | HOFFMANN-LA ROCHE INC. (US) | 1987-09-15 | — | — | US | disclosed |
| EP-0154977-A2 | Glycerin-ether phosphatides, their preparation and use | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1985-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117798-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | LMNA 248/4885CYP2D6 4634/4885CYP2C9 4726/4885 |
| US-10556018-B2 | Compositions and methods for delivery of agents | HDLBP, APOB, TSG101 | LMNA 248/4885CYP2D6 4634/4885CYP2C9 4726/4885 |
| US-20200206362-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | LMNA 248/4885CYP2D6 4634/4885CYP2C9 4726/4885 |
| US-10207010-B2 | Compositions and methods for delivery of agents | HDLBP, APOB, TSG101 | LMNA 248/4885CYP2D6 4634/4885CYP2C9 4726/4885 |
| US-11285222-B2 | Compositions and methods for delivery of agents | HDLBP, APOB, TSG101 | LMNA 248/4885CYP2D6 4634/4885CYP2C9 4726/4885 |
| US-20220265857-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | LMNA 248/4885CYP2D6 4634/4885CYP2C9 4726/4885 |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | LMNA 248/4885CYP2D6 4634/4885CYP2C9 4726/4885 |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | LMNA 248/4885CYP2D6 4634/4885CYP2C9 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.